Herpes Zoster Epidemiological Model's Program: Its Effects on Elderly patients and Their Family Caregivers

Aliaa Mohammed Othman El_afandy^1, and Mayada Taha Mahmoud Sabea¹

¹Lecturers in Community Health Nursing Department, Faculty of Nursing, Helwan University, Egypt

Cite this paper

Aliaa Mohammed Othman El_afandy and Mayada Taha Mahmoud Sabea. Herpes Zoster Epidemiological Model's Program: Its Effects on Elderly patients and Their Family Caregivers. American Journal of Nursing Research. 2018; 6(4):137-146. doi: 10.12691/AJNR-6-4-1

Abstract

Herpes zoster strikes millions of older adults annually worldwide and disables a substantial number of them via postherpetic neuralgia. Aim: This study aimed to evaluate herpes zoster epidemiological model's program: Its effects on elderly patients and their family caregivers. Research design: A quasi-experimental design was used in this study. Setting: The study was conducted at the Out-patient Clinic of the Health Insurance Hospital in Helwan Distract. Subjects: A purposive sample was used to select 50 elderly patients and 50 of their family caregivers, who were included in this study. Tools: Used for data collection included an interviewing questioner, which consists of four parts: I. Socio-demographic characteristics of elderly patient and their family caregiver as age, gender, educational level, and occupation. II. Elderly patients and family caregiver's knowledge regarding herpes zoster as: meaning of the disease, causes, signs and symptoms, complications, and mode of transmission. III. An epidemiological model's information questionnaire that includes three aspects as; person, agent and environment. IV. Elderly patient's and family caregiver's practices regarding herpes zoster toward control and prevention as reported by them such as; patient isolation, using special equipment, using mask and gloves. Results: This study showed, statistically significant improvement of elderly patients' and family caregivers' knowledge, practices, and epidemiological model´s information regarding herpes zoster (3.66±2.401 to 7.70±4.0082, and 2.700±1.675 to 8.260±3.541) (4.140±4.646 to 8.600±2.777and 4.200± 4.458 to 9.240±1.559) (7.62±7.999 to 16.00±4.449 and 7.360±7.745 to 16.460±3.339) respectively post program implementation. Conclusion: Highly statistically significant effect on knowledge and practices of the elderly patients and family caregivers post epidemiological model's program. Recommendations: Dissemination of the epidemiological model for patients and family caregivers of herpes zoster during follow-up visits. An illustrated booklet should be provided with a description of disease control and prevention. Further researches are needed in other areas especially rural areas to estimate the effect of epidemiological model in disease prevention and control.

Keywords

herpes zoster, epidemiological model, elderly patients, family caregivers

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Franco, E., Gabutti, G., Bonanni, P., Conversano, M., Stefano, M.E., Ferro, A., Icardi, G., Antonio M.L., Maggi, S., Rossi, A., Scotti, S., Vitale, F., & Greco, D.: Herpes zoster and its prevention in Italy. Scientific consensus statement Ig Sanita Pubbl,; 70(1): 111-27, Jan-Feb 2014.
[2]	Kawai, K., Berhanu, G.G., & Camilo, J.A.: Systematic review of incidence and complications of herpes zoster: towards a global perspective; bmj Open.; 4(6): E004833, 2014.
[3]	Robert, W., Johnson, M.J., Alvarez-Pasquin, M.B., Elisabetta, F.J., Gaillat, João, G., Clara, M., Labetoulle, J.P., Michel, L.N., Luis, & Thomas, W.: Herpes zoster epidemiology, management, and disease and economic burden in Europe: A multidisciplinary perspective; Ther Adv Vaccines,; 3(4): 109-120, Jul 2016.
[4]	Bloch, K., & Johnson, J.: Varicella zoster virus transmission in the vaccine era: Unmasking the role of herpes zoster. J Infect Dis, 205: 1331-1333, 2014.
[5]	Harriet, J.F., Sara, L.T., & Sinéad, M.L.: The epidemiology and prevention of Herpes Zoster. Current Dermatology Reports, 1(1): 39-47, 2015.
[6]	CDC (2018): Shingles surveillance. Available at https://www.cdc.gov/shingles/surveillance.html.
[7]	Public Health Agency of Canada: Statement on seasonal influenza vaccine for 2014–2015. Canada: Public Health Agency of Canada, 2014.
[8]	WHO: Varicella and Herpes Zoster vaccines: WHO position paper, social determinants and public health programmes, available at: www.who.int/nmh/publications/ncd_report_chapter2.pdf, 2018.
[9]	Sampathkumar, P., Drage, L. A., & Martin, D.P.: Herpes zoster (Shingles) and postherpetic Neuralgia, Mayo Clin Proc.; 84(3): 274-280. 2014.
[10]	Chen, S.Y., Suaya, J.A., & Li, Q.,: Incidence of herpes zoster in patients with altered immune function. Infection; 42:325-34, 2014.
[11]	Cunningham, A.L., Breuer, J., Dwyer, D.E., Gronow, D.W., Helme, R.D., Litt, J.C., Levin, M.J. & MacIntyre, C.R.: The prevention and management of herpes zoster; Med J Aust; 188 (3): 171-176.
[12]	Rothman, K.J.: Causes, Am J Epidemiol; 104: 587-92, 1976.
[13]	CDC: Principle of epidemiology in public health practices, third edition: An introduction to applied epidemiology and biostatistics. available at www.cdc.org/ophss/csels/dsepd/ss1978, 2012.
[14]	Dawson, B.D., & Trapp, R.G.,: Reading the medical literature: Basic & Clinical Biostatistics.(3rd ed.). Newyork: Lange Medical Book/ McGraw–Hill. Medical Publication Division, Ch. 7-9, pp. 161-218 and Ch. 13, pp. 305-314, 2001.
[15]	Wiegering, V., Schick, J., Beer, M., Weissbrich, B., Gattenlohner, S., Girschick, H.J., Liese, J., Schlegel, P.G., Eyrich, M.: Varicella-zoster virus infections in immunocompromised patients - A single centre 6-years analysis. BMC, Pediatrics, 11: 31, 2013.
[16]	Mizukami, A., Sato, K., Adachi, K., Matthews, S., Holl, K., Matsuki, T., Kaise, T., & Curran, D.,: Impact of herpes zoster and post- herpetic neuralgia on health- related quality of life in japanese adults aged 60 years or older: Results from a prospective, observational cohort study, Clin Drug Investig.; 38(1): 29-37. Jan 2018.
[17]	Chayangsu, O., Jiamton, S., Leeyaphan, C., Prasertworonun, N., Omcharoen, V., & Kulthanan, K.: Willingness to pay, quality of life, and knowledge on herpes zoster among Thai patients prior zoster vaccine era. Southeast Asian J Trop Med Public Health, 47: 6, 2016.
[18]	Lee, T.J., CMD, M.D., Hayes, S., Doyle, M.C, Pharm, D., Lee, Y.W., Lew, B.L. & Sim, W.Y.: Awareness, knowledge, and vaccine Acceptability of Herpes Zoster in Korea: A Multicenter Survey of 607 Patients: Ann Dermatol, 27: 5, 2015.
[19]	Roh, N.K., Park, Y.M., Kang H., Choi, G.S., Kim, B.J., Lee, Y.W., Lew B.L., & Sim W.Y.: Awareness, knowledge, and vaccine acceptability of Herpes Zoster in Korea: A Multicenter survey of 607, patients, Ann Dermatol, 27: 5. 2015.
[20]	Aziz, M., Kessler, H., Huhn, G.: Providers' lack of knowledge about herpes zoster in HIV-infected patients is among barriers to herpes zoster vaccination. Int J STD AIDS,; 24(6):433-9, Jun 2013.
[21]	Miyachi, m., & Imafuku, S.: Relationship between prior knowledge about herpes zoster and the period from onset of the eruption to consultation in patients with herpes zoster. J Dermatol ; 43(10): 1184-1187, Oct 2016.
[22]	Lam, A.C., Chan, M.Y., Chou, H.Y., Ho, S.Y., Li, H.L., Lo, .Y., Shek, K.F., To, S.Y., Yam, K.K., & Yeung, I.: A cross-sectional study of the knowledge, attitude, and practice of patients aged 50 years or above towards herpes zoster in an out-patient setting. Hong Kong Med J.,: 23(4):365-73. Epub Aug 2017.
[23]	Yang, T.U., Cheong, H.J., Song, J.Y., Noh, J.Y., & Kim, W.J.: Survey on public awareness, attitudes, and barriers for herpes zoster vaccination in South Korea. Human Vaccines & Immuno therapeutics 11(3):719-726, 2015.
[24]	Saba, J., Fatima, J., Rana, M.M. & Stephen, K.T.: Herpes zoster vaccine awareness among people ≥ 50 years of age and its implications on immunization. Dermatology Online Journal; 18 (8): 2, 2012.
[25]	Wang, J.D., Ford, L.J., Pharm, D., Wingate, L.M., Uroza, S.F., Jaber, N., Smith, C., Randolph, R., Lane, S ., & Foster, S. L.: The effect of pharmacist intervention on herpes zoster vaccination in community pharmacies .J Am Pharm Assoc. 1; 53(1): 46-53, Jan 2013.
[26]	Teeter, B.S., Garza, K.B., Stevenson, T.L., Williamson, M.A., Zeek, M.L., & Westrick, S.C.: Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies. Vaccine, 29; 32(43): 5749-54. Sep 2014.
[27]	Johnson, A.R., McElhaney, B.J., Pedalino, C.B., & Levin, D.M.: Prevention of herpes zoster and its painful and debilitating complications. International Journal of Infectious Diseases 11 (2); S43-S48, 2007.
[28]	Kimberly, B.P., Williamson, M., Stevenson, B.S., Benjamin, S.B., MSaMegan, L.T., & Salisa, C.Z.: Patient vaccination education program through an introductory pharmacy practice experience. Currents in Pharmacy Teaching and Learning, 7 (6), 764-770, November–December 2015.
[29]	Amirthalingam, G., Andrews, N., Keel, P., Mullett, D., Correa, A., de Lusignan, S., & Ramsay, M.: Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: A population-based study; The Lancet Public Health, 3 (2): e82-e90, February 2018.
[30]	Maung, Z.T., Taylor, P.R., Robinson, P.: Patient education for self-referral and on-demand treatment for herpes zoster in lymphoma patients. Leuk Lymphoma, 11: 447-452, 2009.
[31]	Ahrens,W., Krickeberg,K., & Pigeot, I.,: An Introduction to Epidemiology. In: Ahrens W., Pigeot I. (eds) Handbook of Epidemiology. Springer, Berlin, Heidelberg Available at: http://www.springer.com/978-3-540-00566-7, 2015.
[32]	Nganwa, D., Habtemariam, T., Tameru, B., Gerbi, G., Bogale, A., Robnett, V., & Wilson, W.: Applying the epidemiologic problem oriented approach (EPOA) methodology in developing a knowledge and practice base for the modeling of HIV/AIDS, S1-173-7, 2011.